ANSELM ELDERGILL draws attention to a legal case on Tuesday in which a human rights group is challenging the government’s decision to allow the sale of weapons used against Palestinians
Latest editorial
Public pharma v abusive prices: the case of the latest HIV-prevention drug
ALAN ROSSI SILVA argues that Gilead’s HIV prevention drug, while promising, highlights systemic failures in the pharmaceutical industry, showing the need to shift towards state-owned drug development and production
An electron micrograph of HIV-1 virus particles (colourized red) replicating from an HIV-infected H9 T-cell (blue)
The obfuscation of Nazism’s capitalist roots has seen imperialism redeploy fascism again and again — from the killing fields of Guatemala to the war in Ukraine, writes PAWEL WARGAN
From Workers’ Memorial Day to May Day rallies, TOM MORRISON examines the real challenges facing the labour movement as Reform UK’s glossy literature exploits legitimate grievances in traditional left strongholds
Calls have been made for the return to Venezuela of a two-year-old girl currently being held in the US, after being separated from her family by immigration officials, reports SUSAN GREY
In the first of two articles, DANIEL POWELL investigates the causal aspects of the Russo-Ukrainian war as Britain commemorates 80 years since VE Day
LENACAPAVIR, an injectable antiretroviral drug developed by Gilead Sciences, recently made headlines after a Phase 3 clinical trial in South Africa and Uganda showed it to be 100 per cent effective in preventing HIV among women and adolescent girls.
Though hailed as a breakthrough in HIV prevention, lenacapavir serves as a stark reminder of the problems with the pricing of life-saving medicines.
While further data from this study and results from studies involving other populations are needed, lenacapavir could be considered the most durable HIV prevention method to show efficacy among women — a population for who biomedical HIV prevention evidence has been severely limited.
Similar stories
GUILLERMO THOMAS recommends a useful book aimed at informing activists with local examples of solidarity in action around the world
Despite miraculous trial results showing new treatment could halt transmission, corporate greed and patent laws condemn millions to preventable infection and death, write ROX MIDDLETON, LIAM SHAW and MIRIAM GAUNTLETT
